Table 1 Baseline characteristics of renal cell carcinoma patients (n = 114)
Characteristics | N | % |
|---|---|---|
Sex | Â | Â |
male | 69 | 60.5 |
female | 45 | 39.5 |
Age | Â | Â |
median (range) | 65.5 (45-88) | 47.4 |
< 65 | 54 | 52.6 |
> 65 | 60 | Â |
ECOG | Â | Â |
0 | 83 | 72.8 |
1 | 28 | 24.6 |
2 | 3 | 2.6 |
Nephrectomy | Â | Â |
Yes | 108 | 94.7 |
no | 6 | 5.3 |
Time from primary to metastasis | Â | Â |
< 1 year | 56 | 49.1 |
> 1 year | 58 | 50.9 |
Histology | Â | Â |
clear cell | 104 | 91.2 |
non clear cell | 10 | 8.8 |
MSKCC | Â | Â |
favourable | 45 | 39.5 |
intermediate | 67 | 58.7 |
poor | 2 | 1.8 |
Number of metastasis | Â | Â |
1 | 32 | 28.1 |
2 | 54 | 47.4 |
> 3 | 28 | 24.5 |
Location of metastasis | Â | Â |
Lung | 79 | 69.3 |
Liver | 22 | 19.3 |
Bone | 41 | 36 |
Lymph nodes (LN) | 38 | 33.3 |
CNS | 12 | 10.5 |
other | 41 | 36 |
Systemic therapy before first Targeted Agent (TA) | Â | Â |
Cytokines | 54 | 47.4 |
other | 11 | 9.6 |
First targeted agent | Â | Â |
Bevacizumab | 4 | 3.5 |
Sunitinib | 72 | 63.2 |
Sorafenib | 35 | 30.7 |
Temsirolimus | 3 | 2.6 |